Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus and Durvalumab in Resectable NSCLC
NCT04348292Phase 1Terminated
- Sponsor
- Emory University
- Start
- Jan 2021
- Primary completion
- Nov 2022
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sirolimus and durvalumab in non-small cell lung cancer (NSCLC), sponsored by Emory University. Primary endpoints: Treatment-related Adverse Events and Complete Pathologic Response. Started Jan 2021; status: terminated.
02
Drugs
sirolimusdurvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04348292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04348292.